医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mitsui Chemicals Commences Operations at Korean Subsidiary

2016年03月15日 PM01:30
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsui Chemicals, Inc. (TOKYO:4183) (President & CEO: Tsutomu Tannowa) announced that it will commence operations at its new Korean subsidiary, Mitsui Chemicals Korea, Inc., on April 1, 2016. The new company is a restructuring of the Mitsui Chemicals, Inc. Korean Branch which was established on October 1, 2014.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160314005497/en/

Photo of Mitsui Chemicals Korea, Inc. (Photo: Business Wire)

Photo of Mitsui Chemicals Korea, Inc. (Photo: Business Wire)

The new company will form an optimum sales network to further expand Mitsui Chemicals operations in Korea mainly targeting materials for automotive and electrical/electronic products.

 

Outline of Mitsui Chemicals Korea, Inc.

Company name   Mitsui Chemicals Korea, Inc.
Capital 1 billion wong(approx. 100 million yen)
Location Yongsan Building 9th floor, 273 Hangang-daero, Yongsan-gu, Seoul, Korea
President Hiroyuki Furukawa
Telephone number   +82-2-702-3134
 

Background
Korea is an important market with world class automobile and electrical/electronic manufacturers. For the Mitsui Chemicals Group, which lists the mobility segment as one of three priority targets, Korea is extremely attractive with good potentials for business growth and expansion. In addition, the Korean market also holds equally good potential for the Group’s other two priority business areas of healthcare and food & packaging.

Mitsui Chemicals Korean branch was established in October 2014 to collect information on the Korean market and provide cutting edge service to customers with an eye on a future status upgrade to that of a local subsidiary with sales functions to further bolster the Company’s business interest in the country. Mitsui Chemicals will continue to strengthen its business development in Korea while fulfilling its role as a good corporate citizen.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160314005497/en/

CONTACT

Mitsui Chemicals, Inc.
Takashi Kawamoto, +81-3-6253-2100
Corporate
Communications Div.
takashi.kawamoto@mitsuichemicals.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続